Multidrug resistance in cancer: role of ATP–dependent transporters
The DOI matches its Crossref record; 167 of the 168 references it cites were found in a registry or an index.
Abstract
Chemotherapeutics are the most effective treatment for metastatic tumours. However, the ability of cancer cells to become simultaneously resistant to different drugs--a trait known as multidrug resistance--remains a significant impediment to successful chemotherapy. Three decades of multidrug-resistance research have identified a myriad of ways in which cancer cells can elude chemotherapy, and it has become apparent that resistance exists against every effective drug, even our newest agents. Therefore, the ability to predict and circumvent drug resistance is likely to improve chemotherapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A common mechanism of multidrug resistance consists in the overexpression of cancer drug–extruding ABC transporters in malignant cells (58).”
From SRC kinase drives multidrug resistance induced by KRAS-G12C inhibition (2024) · cites this paper as [58]
In the citing paper
“Prior exposure to taxanes during treatment of mCRPC can induce resistance mechanisms, including upregulation of efflux pumps or mutations in tubulin, that may compromise the efficacy of microtubule inhibitor-based ADCs246,247.”
From The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer (2025) · cites this paper as [247]
Citations
Cites
A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
Juliano, R. L., & Ling, V. (1976) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(76)90160-7 · Cited by 3,296
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104 · cited 1×
“But why can some patients be cured by these approaches and others respond transiently or incompletely? Host and tumour genetic alterations, epigenetic changes and tumour environment all seem to contribute to the complex story of cancer drug resistanc”
BackgroundOverexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell Line
Cole, S. P. C., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M. V., & Deeley, R. G. (1992) · Science · doi:10.1126/science.1360704 · Cited by 3,037
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
Lowe, S. W., Ruley, H. E., Jacks, T., & Housman, D. E. (1993) · Cell · doi:10.1016/0092-8674(93)90719-7 · Cited by 2,925
A multidrug resistance transporter from human MCF-7 breast cancer cells
Doyle, L. A., Yang, W., Abruzzo, L. V., Krogmann, T., Gao, Y., Rishi, A. K., & Ross, D. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15665 · Cited by 2,322 · cited 1×
“cgi?l=9429">ABCG2 — also known as MXR (mitoxantrone-resistance gene), BCRP (breast cancer resistance protein) or ABC-P (ABC transporter in placenta”
BackgroundNormalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
Jain, R. K. (2001) · Nature Medicine · doi:10.1038/nm0901-987 · Cited by 2,184 · cited 1×
“Recent studies have emphasized the importance of the tumour vasculature and an appropriate pressure gradient for adequate drug delivery to the tumou”
BackgroundBIOCHEMICAL, CELLULAR, AND PHARMACOLOGICAL ASPECTS OF THE MULTIDRUG TRANSPORTER
Ambudkar, S. V., Dey, S., Hrycyna, C. A., Ramachandra, M., Pastan, I., & Gottesman, M. M. (1999) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.39.1.361 · Cited by 2,059 · cited 1×
“asp?DrugCode=A%2D10166&DrugName=PACLITAXEL%2CSEMI%2DSYNTHETIC+INTRAVEN%2E&DrugType=1">paclitaxel”
Self-citationChen, C.-J., Chin, J. E., Ueda, K., Clark, D. P., Pastan, I., Gottesman, M. M., & Roninson, I. B. (1986) · Cell · doi:10.1016/0092-8674(86)90595-7 · Cited by 1,898
Self-citationA family of drug transporters: the multidrug resistance-associated proteins
Borst, P., Evers, R., Kool, M., & Wijnholds, J. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.16.1295 · Cited by 1,751 · cited 1×
“The discovery of MRP1 stimulated a genomic search for homologues, leading to the discovery of eight additional members of the ABCC subfamily of transporters, of which six have been studied in some detai”
BackgroundThe Human ATP-Binding Cassette (ABC) Transporter Superfamily
Dean, M., Rzhetsky, A., & Allikmets, R. (2001) · Genome Research · doi:10.1101/gr.184901 · Cited by 1,748
Research works printed but not linked: 3
- Solary, E. et al. Sufficient levels of quinine in the serum circumvent the multidrug resistance of the human leukemic cell line K562/ADM. Cancer 68, 1714–1719 (1991). · doi:10.1002/1097-0142(19911015)68:8<1714::aid-cncr2820680811>3.0.co;2-2
- Abraham, J. et al. A phase I study of the novel P-glycoprotein (PGP) antagonist, XR9576 in combination with vinorelbine. Proc. Am. Soc. Clin. Oncol. 20, 287 (2001).
- Fedeli, L. et al. Pharmacokinetics of vincristine in cancer patients treated with nifedipine. Cancer 64, 1805–1811 (1989). · doi:10.1002/1097-0142(19891101)64:9<1805::aid-cncr2820640908>3.0.co;2-d
Cited by
Items 501–600 of 1,041
ROS and Brain Gliomas: An Overview of Potential and Innovative Therapeutic Strategies
Rinaldi, M., Caffo, M., Minutoli, L., Marini, H. R., Abbritti, R. V., Squadrito, F., Trichilo, V., Valenti, A., Barresi, V., Altavilla, D., et al. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17060984 · Cited by 167
“Redox resetting has been implicated in drug resistance at multiple levels, including elevated drug efflux, altered drug metabolism and mutated drug targets [102].”
BackgroundJanuchowski, R., Zawierucha, P., Andrzejewska, M., Ruciński, M., & Zabel, M. (2012) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2012.11.011 · Cited by 150
MDR1 Genotype-related Pharmacokinetics: Fact or Fiction?
Sakaeda, T. (2005) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.20.391 · Cited by 160
Khan, M. N., Yi, F., Rasul, A., Li, T., Wang, N., Gao, H., Gao, R., & Ma, T. (2012) · IUBMB Life · doi:10.1002/iub.1068 · Cited by 151
“On the contrary, higher level of GSH in cells is related to apoptosis resistance (12).”
BackgroundCancer stem cells and oncology therapeutics
Al-Hajj, M. (2007) · Current Opinion in Oncology · doi:10.1097/cco.0b013e328011a8d6 · Cited by 148
Yadav, S. K., van Vlerken, L. E., Little, S. R., & Amiji, M. M. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0790-y · Cited by 152
“Cellular mechanisms of drug resistance have been intensively studied and several major classes have been identiWed [5, 6].”
BackgroundAdeli, M., Soleyman, R., Beiranvand, Z., & Madani, F. (2013) · Chemical Society Reviews · doi:10.1039/c3cs35431h · Cited by 163
Zhang, W., Wang, F., Wang, Y., Wang, J., Yu, Y., Guo, S., Chen, R., & Zhou, D. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.04.001 · Cited by 152
“MDR is a leading cause of cancer chemotherapy failure [5,6], mainly caused by cancer cell surface overexpressed efflux transporters which can effectively efflux out therapeutic drugs, preventing drug accumulation and compromising therapeutic efficacy [7-12].”
BackgroundMetabolic shift toward oxidative phosphorylation in docetaxel resistant prostate cancer cells
Ippolito, L., Marini, A., Cavallini, L., Morandi, A., Pietrovito, L., Pintus, G., Giannoni, E., Schrader, T. H., Puhr, M., Chiarugi, P., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11301 · Cited by 149
“To date, several factors have been associated with docetaxel resistance, including expression of different isoforms of β-tubulin [3], activation of drug efflux pumps [4], Research Paper”
BackgroundIvermectin reverses the drug resistance in cancer cells through EGFR/ERK/Akt/NF-κB pathway
Jiang, L., Wang, P., Sun, Y.-J., & Wu, Y.-J. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1251-7 · Cited by 146
Natural killer cells kill human melanoma cells with characteristics of cancer stem cells
Pietra, G., Manzini, C., Vitale, M., Balsamo, M. L., Ognio, E., Boitano, M., Queirolo, P., Moretta, L., & Mingari, M. C. (2009) · International Immunology · doi:10.1093/intimm/dxp047 · Cited by 158
Small Molecules for Active Targeting in Cancer
Kue, C. S., Kamkaew, A., Burgess, K., Kiew, L. V., Chung, L. Y., & Lee, H. B. (2016) · Medicinal Research Reviews · doi:10.1002/med.21387 · Cited by 141
Nanomedicine-enabled chemotherapy-based synergetic cancer treatments
Wu, W., Pu, Y., & Shi, J. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-01181-z · Cited by 160
Bergmann, S., Royer-Pokora, B., Fietze, E., Jürchott, K., Hildebrandt, B., Trost, D., Leenders, F., Claude, J.-C., Theuring, F., Bargou, R., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4056 · Cited by 145
“In human breast cancer, nuclear localization of YB-1 is associated with intrinsic MDR1 gene expression (6), and the MDR1 gene product P-glycoprotein plays a major role in the development of a multidrug-resistant tumor phenotype (8).”
BackgroundSauna, Z. E., & Ambudkar, S. V. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0155 · Cited by 147
“conferring multidrug resistance to cancer cells (4).”
Pathways to Breast Cancer Recurrence
Ahmad, A. (2013) · ISRN Oncology · doi:10.1155/2013/290568 · Cited by 172
“Irrespective of the underlying breast cancer subtype, a large number of advanced stage breast cancers are marked by metastases to lymph nodes, and, overall, the presence of axillary lymph node metastases is associated with considerable poor disease-free as well as overall survival [14].”
BackgroundSerine protease HtrA1 modulates chemotherapy-induced cytotoxicity
CHIEN, J. R. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27698 · Cited by 146
“Resistance to paclitaxel has been attributed to increased drug metabolism, overexpression of P-glycoprotein (6), changes in mitotic checkpoint regulation, alterations in MT-associated proteins or tubulin isotype expression, and mutations or posttranslational modifications of tubulins (3).”
BackgroundCryo-EM structure of the ABCG2 E211Q mutant bound to estrone 3-sulfate and 5D3-Fab: 6hco
Manolaridis, I., Jackson, S. M., Taylor, N. M. I., Kowal, J., Stahlberg, H., & Locher, K. P. (2018) · Worldwide Protein Data Bank · doi:10.2210/pdb6hco/pdb · Cited by 145
Alakhova, D. Y., Rapoport, N. Y., Batrakova, E. V., Timoshin, A. A., Li, S., Nicholls, D. G., Alakhov, V. Y., & Kabanov, A. V. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.09.026 · Cited by 145
“Multidrug resistance (MDR) is one of themajor obstacles to successful chemotherapy [1].”
A Folate Receptor-Targeting Nanoparticle Minimizes Drug Resistance in a Human Cancer Model
Wang, X., Li, J., Wang, Y., Koenig, L., Gjyrezi, A., Giannakakou, P., Shin, E. H., Tighiouart, M., Chen, Z. (., Nie, S., et al. (2011) · ACS Nano · doi:10.1021/nn200739q · Cited by 143
“membrane-associated P-gp results in resistance to paclitaxel and other chemotherapeutic drugs.(3) This type of resistance is”
Recent Advances on Inorganic Nanoparticle-Based Cancer Therapeutic Agents
Wang, F., Li, C., Cheng, J., & Yuan, Z. (2016) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph13121182 · Cited by 155
“In addition, the relapse and multi-drug resistance make the current treatments ineffective toward partial cancers [3].”
van Vlerken, L. E., Duan, Z., Little, S. R., Seiden, M. V., & Amiji, M. M. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800030k · Cited by 142
Katayama, R., Sakashita, T., Yanagitani, N., Ninomiya, H., Horiike, A., Friboulet, L., Gainor, J. F., Motoi, N., Dobashi, A., Sakata, S., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2015.12.009 · Cited by 141
“ABC transporters such as P-gp (ABCB1) or BCRP (ABCG2), play an important role in chemotherapeutic drug resistance (Gottesman et al., 2002).”
BackgroundRepurposing Cationic Amphiphilic Antihistamines for Cancer Treatment
Ellegaard, A.-M., Dehlendorff, C., Vind, A. C., Anand, A., Cederkvist, L., Petersen, N. H. T., Nylandsted, J., Stenvang, J., Mellemgaard, A., Østerlind, K., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.06.013 · Cited by 141
“Moreover, chemotherapy-treated cancer cells often acquire an ability to efflux the chemotherapeutic drugs by increasing the expression of multidrug resistance (MDR)-associated P-glycoproteins of the ATPbinding cassette transporter family (Gottesman et al., 2002, Chang, 2011).”
BackgroundCancer Drug Resistance: A Brief Overview from a Genetic Viewpoint
Rueff, J., & Rodrigues, A. S. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3347-1_1 · Cited by 158
Clock and ATF4 transcription system regulates drug resistance in human cancer cell lines
IGARASHI, T., Izumi, H., Uchiumi, T., Nishio, K., Arao, T., Tanabe, M., Uramoto, H., Sugio, K., Yasumoto, K., Sasaguri, Y., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210289 · Cited by 158
“Membrane transporters of the ABC superfamily function as a pump, and can lead to resistance against multiple anticancer agents (Gottesman et al., 2002; Oncogene Szakacs et al., 2006).”
BackgroundMechanisms of evasive resistance to anti-VEGF therapy in glioblastoma
Lu, K. V., & Bergers, G. (2013) · CNS Oncology · doi:10.2217/cns.12.36 · Cited by 138
Bao, Y., Guo, Y., Zhuang, X., Li, D., Cheng, B., Tan, S., & Zhang, Z. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500384d · Cited by 146
Chemistry of DNA minor groove binding agents
Khan, G. S., Shah, A., Rehman, Z., & Barker, D. L. A. (2012) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/j.jphotobiol.2012.07.003 · Cited by 143
Shen, J., Yin, Q., Chen, L., Zhang, Z., & Li, Y. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.08.007 · Cited by 143
Liu, S., Zhou, S., Tian, L., Guo, E., Luan, Y., Zhang, J., & Li, S. (2011) · BMC Genomics · doi:10.1186/1471-2164-12-491 · Cited by 146
“ABCB ABCB1 was the first human ABC transporter to be cloned and characterized through its function to confer a multidrug resistance (MDR) phenotype to cancer, and later studies revealed several more MDRs in the ABCB subfamily [18].”
BackgroundImproving Cancer Treatment via Mathematical Modeling: Surmounting the Challenges Is Worth the Effort
Michor, F., & Beal, K. P. (2015) · Cell · doi:10.1016/j.cell.2015.11.002 · Cited by 164
“Cancer research and oncology has entered a new era of targeted therapy (Sawyers, 2004) and patient-tailored therapeutic intervention (Shrager and Tenenbaum, 2014), but resistance (Gottesman et al., 2002; Holohan et al., 2013) and tumor heterogeneity (Anderson et al.”
Role of ABC Transporters in the Pathogenesis of Alzheimer’s Disease
Abuznait, A. H., & Kaddoumi, A. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn300077c · Cited by 135
Wei, X., Wang, Y., Xiong, X., Guo, X., Zhang, L., Zhang, X., & Zhou, S. (2016) · Advanced Functional Materials · doi:10.1002/adfm.201603336 · Cited by 151
Advanced Materials for Co‐Delivery of Drugs and Genes in Cancer Therapy
Khan, M., Ong, Z. Y., Wiradharma, N., Attia, A. B. E., & Yang, Y. (2012) · Advanced Healthcare Materials · doi:10.1002/adhm.201200109 · Cited by 141
Berger, W., Setinek, U., Hollaus, P. H., Zidek, T., Steiner, E., Elbling, L., Cantonati, H., Attems, J., Gsur, A., & Micksche, M. (2005) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-004-0653-9 · Cited by 142
“P-gp, the archetype of a drug-resistance ABC-transporter encoded by the MDR1 gene, causes chemoresistance of diverse cancer types (Gottesman et al. 2002).”
BackgroundCheung, S., Cheung, P. F., Cheng, C. K. C., Wong, N. C. L., & Fan, S. T. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.07.049 · Cited by 142
The Inhibitor Ko143 Is Not Specific for ABCG2
Weidner, L. D., Zoghbi, S. S., Lu, S., Shukla, S., Ambudkar, S. V., Pike, V. W., Mulder, J., Gottesman, M. M., Innis, R. B., & Hall, M. D. (2015) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.225482 · Cited by 141
“These membrane-bound ATP-driven efflux pumps serve to protect tissues by actively effluxing xenobiotics from cells into the extracellular space (Gottesman et al., 2002).”
BackgroundSelf-citationTamura, A., Watanabe, M., Saito, H., Nakagawa, H., Kamachi, T., Okura, I., & Ishikawa, T. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.023556 · Cited by 141
“It has been reported that mutations of certain ABC protein genes are causative for several genetic disorders in humans (Dean et al., 2001; Borst and Elferink, 2002; Gottesman et al., 2002; Ishikawa, 2003; Varadi et al., 2003).”
BackgroundAnthracycline nano-delivery systems to overcome multiple drug resistance: A comprehensive review
Ma, P., & Mumper, R. J. (2013) · Nano Today · doi:10.1016/j.nantod.2013.04.006 · Cited by 138
Nanoparticle delivery of anticancer drugs overcomes multidrug resistance in breast cancer
Yuan, Y., Cai, T., Xia, X., Zhang, R., Chiba, P., & Cai, Y. (2016) · Drug Delivery · doi:10.1080/10717544.2016.1178825 · Cited by 149
“The protein, which belongs to the ABCG subfamily of ABC transporters, is an inverted halftransporter composed of an N-terminal nucleotide-binding site and a carboxyterminal transmembrane domain, which contains six membrane spanning helices (Gottesman et al., 2002; Gradhand & Kim, 2008).”
BackgroundInfluentialThe therapeutic potential of targeting ABC transporters to combat multi-drug resistance
Bugde, P., Biswas, R., Merien, F., Lu, J., Liu, D.-X., Chen, M., Zhou, S., & Li, Y. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1310841 · Cited by 135
“ubicin and daunorubicin) [1,28,55,56], antibiotics (e.”
Wang, S., Liu, X., Chen, S., Liu, Z., Zhang, X., Liang, X., & Li, L. (2018) · ACS Nano · doi:10.1021/acsnano.8b05639 · Cited by 147
Drug delivery systems based on CD44-targeted glycosaminoglycans for cancer therapy
Li, M., Sun, J., Zhang, W., Zhao, Y., Zhang, S., & Zhang, S. (2020) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2020.117103 · Cited by 150
Isolation and Identification of Cancer Stem-Like Cells in Esophageal Carcinoma Cell Lines
Huang, D., Gao, Q., Guo, L., Zhang, C., Jiang, W. B., Li, H., Wang, J., Xiao-hong, H., Shi, Y., & Lu, S. (2008) · Stem Cells and Development · doi:10.1089/scd.2008.0033 · Cited by 148
“In addition, the various types of ATP-binding cassette (ABC) transporters may contribute to drug resistance in many cancers by pumping the drugs out of the cells [6].”
Radiobiology goes 3D: How ECM and cell morphology impact on cell survival after irradiation
Eke, I., & Cordes, N. (2011) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2011.06.007 · Cited by 145
Huang, M., Zhang, D., Wu, J. Y., Xing, K., Yeo, E., Li, C., Zhang, L., Holland, E., Yao, L., Qin, L., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay7522 · Cited by 139
Lakkakula, J. R., Gujarathi, P., Pansare, P., & Tripathi, S. (2021) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2021.117696 · Cited by 138
Sissung, T. M., Baum, C. E., Deeken, J. F., Price, D. K., Aragon‐Ching, J. B., Steinberg, S. M., Dahut, W. L., Sparreboom, A., & Figg, W. D. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4230 · Cited by 155
iRGD Peptide as a Tumor-Penetrating Enhancer for Tumor-Targeted Drug Delivery
Kang, S., Lee, S., & Park, S. (2020) · Polymers · doi:10.3390/polym12091906 · Cited by 139
Conde, J., Oliva, N., & Artzi, N. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1421229112 · Cited by 146
Hopper-Borge, E. A., Xu, X. Q., Shen, T., Shi, Z., Chen, Z., & Kruh, G. D. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1420 · Cited by 140
“ATP-binding cassette (ABC) transporters are involved in resistance by virtue of their ability to extrude drugs from the cell (1, 2).”
Mechanisms of Drug Resistance in High-Grade Serous Ovarian Cancer
Freimund, A. E., Beach, J. A., Christie, E. L., & Bowtell, D. D. L. (2018) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2018.07.007 · Cited by 161
Current Advances in Black Phosphorus‐Based Drug Delivery Systems for Cancer Therapy
Liu, W., Dong, A., Wang, B., & Zhang, H. (2021) · Advanced Science · doi:10.1002/advs.202003033 · Cited by 147
Cancer cell adaptation to chemotherapy
Di Nicolantonio, F., Mercer, S. J., Knight, L. A., Gabriel, F. G., Whitehouse, P. A., Sharma, S., Fernando, A., Glaysher, S., Di Palma, S., Johnson, P., et al. (2005) · BMC Cancer · doi:10.1186/1471-2407-5-78 · Cited by 133
“Membrane proteins such as MDR1/P-gp, multi-drug resistance protein 1 (MRP1) and major vault protein (MVP) have been demonstrated to confer resistance to epirubicin by pumping the cytotoxic drug out of cells [16].”
BackgroundMembrane cholesterol selectively modulates the activity of the human ABCG2 multidrug transporter
Telbisz, Á., Müller, M., Özvegy‐Laczka, C., Homolya, L., Szente, L., Váradi, A., & Sarkadi, B. (2007) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2007.06.026 · Cited by 139
“026 the blood–brain barrier, and the protein is present at high levels in stem cells, currently with an unknown physiological function [1–5].”
BackgroundInfluentialS Phase Assembly of Centromeric Heterochromatin and Cohesion
Bailis, J. M., & Forsburg, S. L. (2004) · Cell Cycle · doi:10.4161/cc.3.4.799 · Cited by 139
Koch, R., Aung, T., Vogel, D., Chapuy, B., Wenzel, D., Becker, S., Sinzig, U., Venkataramani, V., von Mach, T., Jacob, R., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0577 · Cited by 142
“As amajor resistance mechanism, ATP-binding cassette (ABC) transporter proteins were discovered to shuttle anthracyclines across the plasma membrane into the extracellular space (13, 32).”
BackgroundNie, X., Xia, L., Wang, H., Chen, G., Wu, B., Zeng, T., Hong, C., Wang, L., & You, Y. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b11291 · Cited by 138
Hazlehurst, L. A., Enkemann, S. A., Beam, C. A., Argilagos, R. F., Painter, J. S., Shain, K. H., Saporta, S., Boulware, D. C., Moscinski, L. C., Alsina, M., et al. (2003) · PubMed · Cited by 155
Reversal of doxorubicin resistance in breast cancer by mitochondria-targeted pH-responsive micelles
Yu, P., Yu, H., Guo, C., Cui, Z., Chen, X., Yin, Q., Zhang, P., Yang, X., Cui, H., & Li, Y. (2014) · Acta Biomaterialia · doi:10.1016/j.actbio.2014.12.001 · Cited by 137
Aryal, M., Vykhodtseva, N., Zhang, Y.-Z., & McDannold, N. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.02.033 · Cited by 129
“Doxorubicin is a substrate for the efflux pump P-glycoprotein, which is present on normal blood vessels in the brain and in some cancer cells [73].”
BackgroundRahikkala, A., Pereira, S. A. P., Figueiredo, P., Passos, M. L. C., Araújo, A. R. T. S., Saraiva, M. L. M. F. S., & Santos, H. A. (2018) · Advanced Biosystems · doi:10.1002/adbi.201800020 · Cited by 142
Song, X., Zhang, Z., Zhu, J., Wen, Y., Zhao, F., Lei, L., Phan-Thien, N., Khoo, B. C., & Li, J. (2020) · Biomacromolecules · doi:10.1021/acs.biomac.0c00077 · Cited by 136
Khezri, M. R., Jafari, R., Yousefi, K., & Zolbanin, N. M. (2022) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2022.104787 · Cited by 149
Loganzo, F., Discafani, C. M., Annable, T., Beyer, C. F., Musto, S., Hari, M., Tan, X., Hardy, C., Hernandez, R., Baxter, M., et al. (2003) · PubMed · Cited by 162
Self-citationLiu, W., Baer, M. R., Bowman, M. J., Pera, P., Zheng, X., Morgan, J., Pandey, R. A., & Oseroff, A. R. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1599 · Cited by 136
Selenium Cytotoxicity in Cancer
Wallenberg, M., Misra, S., & Björnstedt, M. (2014) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12207 · Cited by 145
“19 The most well studied ABC-transporters related to drug resistance are the pglycoprotein (P-gp) resistance protein 1 (MDR1) (ABCB1), multi resistant protein 1 (MRP1) (ABCC1) and breast cancer resistance protein (BCRP) (ABCG2), also known as ABC-P (ABC transporter in placenta) [204].”
BackgroundGanesh, S., Iyer, A. K., Weiler, J., Morrissey, D. V., & Amiji, M. M. (2013) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2013.29 · Cited by 134
Chiarini, F., Sole, M. D., Mongiorgi, S., Gaboardi, G. C., Cappellini, A., Mantovani, I., Follo, M. Y., McCubrey, J. A., & Martelli, A. M. (2008) · Leukemia · doi:10.1038/leu.2008.79 · Cited by 139
Redox Modulating NRF2: A Potential Mediator of Cancer Stem Cell Resistance
Ryoo, I.-G., Lee, S.-H., & Kwak, M.-K. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/2428153 · Cited by 132
“Recent studies are expanding our knowledge about the biological implications of ROS in cancer stem cells (CSCs), which are small subpopulation of cancer cells responsible for tumorigenesis and tumor progression and relapse.”
BackgroundSmart Drug-Delivery Systems for Cancer Nanotherapy
Sánchez‐Moreno, P., Ortega-Vinuesa, J. L., Peula-García, J. M., Marchal, J. A., & Boulaiz, H. (2016) · Current Drug Targets · doi:10.2174/1389450117666160527142544 · Cited by 135
“P-glycoprotein is the best known and most extensively investigated mechanism of drug resistance [19].”
BackgroundSun, L., Wang, D., Chen, Y., Wang, L., Huang, P., Li, Y., Liu, Z., Yao, H., & Shi, J. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.04.028 · Cited by 136
Role of the tumor microenvironment in regulating apoptosis and cancer progression
Yaacoub, K., Pedeux, R., Tarte, K., & Guillaudeux, T. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.05.012 · Cited by 135
Gao, Y., Foster, R., Yang, X., Feng, Y., Shen, J. K., Mankin, H. J., Hornicek, F. J., Amiji, M. M., & Duan, Z. (2015) · Oncotarget · doi:10.18632/oncotarget.3220 · Cited by 144
“It has been recognized as one of the well characterized mechanism for resistant to drug, including paclitaxel [36, 37].”
BackgroundGu, J., Wang, Y., Wang, X., Zhou, D., Shao, C., Zhou, M., & He, Z. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.06.039 · Cited by 135
RetractedPharmacogenetics/genomics of membrane transporters in cancer chemotherapy
Huang, Y. S. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9050-6 · Cited by 144
“Recent reports have shown that genetic polymorphisms in ABCB1 gene are one of the most important determinants for its expression and function [5] and affect response to pharmacotherapy for many diseases [16].”
BackgroundInfluentialMechanisms of resistance to self-produced toxic secondary metabolites in plants
Sirikantaramas, S., Yamazaki, M., & Saito, K. (2007) · Phytochemistry Reviews · doi:10.1007/s11101-007-9080-2 · Cited by 154
“In human cancer cells, a number of reports have shown that the involvement of a transporter or a mutation in tubulin confers resistance to these drugs (Ueda et al. 1987; Kavallaris et al. 1997; Ranganathan et al. 1998; for review, see Gottesman et al. 2002).”
BackgroundHypoxia Dictates Metabolic Rewiring of Tumors: Implications for Chemoresistance
Belisario, D. C., Kopecka, J., Pasino, M., Akman, M., De Smaele, E., Donadelli, M., & Riganti, C. (2020) · Cells · doi:10.3390/cells9122598 · Cited by 133
“Pgp belongs to the adenosine triphosphate (ATP)-binding cassette (ABC) transporters family and effluxes several chemotherapeutic drugs unrelated for structure and mechanism of action, contributing to a multidrug resistance (MDR) phenotype [147].”
BackgroundMartín, V., Sánchez‐Sánchez, A. M., Herrera, F., Gomez‐Manzano, C., Fueyo-Margareto, J., Vega, M. A. Á., Antolín, I., & Rodríguez, C. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.188 · Cited by 133
“2010 www.bjcancer.com | DOI:10.1038/bjc.2013.188 mechanisms responsible for multidrug resistance in cancer cells (Gottesman et al, 2002).”
BackgroundInfluentialWen, Y. F., Zhang, W., Gong, N., Wang, Y., Guo, H., Guo, W., Wang, P. C., & Liang, X. (2017) · Nanoscale · doi:10.1039/c7nr03129g · Cited by 135
Hypoxic tumor microenvironment: Implications for cancer therapy
Roy, S., Kumaravel, S., Sharma, A., Duran, C. L., Bayless, K. J., & Chakraborty, S. (2020) · Experimental Biology and Medicine · doi:10.1177/1535370220934038 · Cited by 141
“MDR1 overexpression (both before and after chemotherapy) is associated with intrinsic as well as acquired drug resistance in hepatic and renal cancers along with leukemia and lymphoma.(132,133) MDR1 is found to be highly expressed on the surface of epithelial cells forming the lining of excretory organs like colon, re…”
BackgroundThe Breast Cancer Stem Cells Traits and Drug Resistance
Zheng, Q., Zhang, M., Zhou, F., Zhang, L., & Meng, X. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.599965 · Cited by 140
“, 2020): on the cell envelope, ATP-binding cassette transporter can decrease the concentration of intracellular anthracyclines (Gottesman et al., 2002; Sun et al., 2015).”
BackgroundPopulational adaptive evolution, chemotherapeutic resistance and multiple anti-cancer therapies
Lorz, A., Lorenzi, T., Hochberg, M., Clairambault, J., & Benoît Perthame, B. (2012) · ESAIM Mathematical Modelling and Numerical Analysis · doi:10.1051/m2an/2012031 · Cited by 146
“A typical example is the release of resistance proteins such as P-gp and other ABC transporters (ATP Binding Cassette), and studies on large human cohorts have shown their correlation with resistance in Acute Myeloid Leukemia [35]), since they promote the efflux of toxic molecules from leukaemic cells [10, 24].”
Tsouris, V., Joo, M. K., Kim, S. H., Kwon, I. C., & Won, Y. (2014) · Biotechnology Advances · doi:10.1016/j.biotechadv.2014.05.006 · Cited by 135
Zhang, X.-Q., Xu, X., Lam, R. T.-T., Giljohann, D. A., Ho, D., & Mirkin, C. A. (2011) · ACS Nano · doi:10.1021/nn201446c · Cited by 132
Resistance to imatinib mesylate in chronic myeloid leukaemia
Melo, J. V., & Chuah, C. T. H. (2006) · Cancer Letters · doi:10.1016/j.canlet.2006.07.010 · Cited by 132
“This is mediated by an increased expression at the cell surface of the MDR1 gene product, Pgp, an energy dependent efflux pump, which reduces intracellular drug concentrations and leads to ineffective levels of the drug reaching its target [44,45].”
BackgroundNanomedicine-mediated cancer stem cell therapy
Shen, S., Xia, J., & Wang, J. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.09.037 · Cited by 135
“multidrug resistance as they provide cells with a unique defence mechanism by significantly decreasing the cellular accumulation of structurally and mechanistically diverse therapeutic agents [58].”
BackgroundNanogels as target drug delivery systems in cancer therapy: A review of the last decade
Attama, A. A., Nnamani, P. O., Onokala, O. B., Ugwu, A. A., & Onugwu, A. L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.874510 · Cited by 147
“The use of monotherapy treatment is more susceptible to drug resistance because constant treatment with a single agent makes cancer cells to recruit alternative salvage pathway (Gottesman and Fojo, 2002; Khdair et al., 2010).”
BackgroundNew horizons in the development of antiepileptic drugs: Innovative strategies
Löscher, W., & Schmidt, D. (2006) · Epilepsy Research · doi:10.1016/j.eplepsyres.2006.03.014 · Cited by 147
Novel natural compounds from endophytic fungi with anticancer activity
Li, S., Zhang, X., Wang, X., & Zhao, C. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.07.015 · Cited by 131
New insights on sorafenib resistance in liver cancer with correlation of individualized therapy
Zhang, C., Wei-Qi, J., & Jin, D. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188382 · Cited by 138
Zhao, M., Lei, C., Yang, Y., Bu, X., Ma, H., Gong, H., Liu, J., Fang, X., Hu, Z., & Fang, Q. (2015) · PLoS ONE · doi:10.1371/journal.pone.0131429 · Cited by 144
“Cells resist PTX were found to exhibit cross-resistance to a variety of other hydrophobic drugs and to have elevated levels of P-gp[10].”
BackgroundInfluentialKubota, H., Ishihara, H., Langmann, T., Schmitz, G., Stieger, B., Wieser, H. G., Yonekawa, Y., & Frei, K. (2005) · Epilepsy Research · doi:10.1016/j.eplepsyres.2005.11.011 · Cited by 141
“From the currently 48 ABC transporters, one-third of them are known to confer drug resistance (Borst et al., 2000; Gottesman et al., 2002; Langmann et al., 2003).”
Gouazé‐Andersson, V., Yu, J. Y., Bleicher, R. J., Han, T.-Y., Liu, Y., Wang, H., Gottesman, M. M., Bitterman, A., Giuliano, A. E., & Cabot, M. C. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.633.3.5 · Cited by 140
Self-citationChattopadhyay, R., Das, S., Maiti, A. K., Boldogh, I. R., Xie, J., Hazra, T. K., Kohno, K., MITRA, S. P., & Bhakat, K. K. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00244-08 · Cited by 144
“Resistance to many common anticancer drugs often occurs due to the enhanced expression of ATP-binding cassette (ABC) transporter proteins (6, 20).”
BackgroundA subset of annular lipids is linked to the flippase activity of an ABC transporter
Bechara, C., Nöll, A., Morgner, N., Degiacomi, M. T., Tampé, R., & Robinson, C. V. (2015) · Nature Chemistry · doi:10.1038/nchem.2172 · Cited by 124
Inhibition of ABCB1 Expression Overcomes Acquired Docetaxel Resistance in Prostate Cancer
Zhu, Y., Liu, C., Nadiminty, N., Lou, W., Tummala, R., Evans, C. P., & Gao, A. C. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0208 · Cited by 124
Sodium Dependent Multivitamin Transporter (SMVT): A Potential Target for Drug Delivery
Dutt Vadlapudi, A., Krishna Vadlapatla, R., & K. Mitra, A. (2012) · Current Drug Targets · doi:10.2174/138945012800675650 · Cited by 118
“Though these transporters are called as drug-resistant pumps, these proteins are expressed in many normal tissues mediating cellular transport of endogenous substrates [16].”
BackgroundWang, D., Zhou, J., Chen, R., Shi, R., Wang, C., Lu, J., Zhao, G., Xia, G., Zhou, S. X., Liu, Z., et al. (2017) · Chemistry of Materials · doi:10.1021/acs.chemmater.6b05215 · Cited by 133
Metadata
- Authors
- Gottesman, M. M., Fojo, T., & Bates, S. E.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Fojo, Tito
- Venue
- Nature Reviews Cancer
- Published
- 2002-01-01
- Volume
- 2
- Issue
- 1
- Pages
- 48-58
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2006434892
- Cited by
- 5,536
- References
- 168
- Citations by year
- 2026: 144 · 2025: 173 · 2024: 183 · 2023: 228 · 2022: 231 · 2021: 257 · 2020: 305 · 2019: 281 · 2018: 318 · 2017: 322 · 2016: 329 · 2015: 333 · 2014: 326 · 2013: 296 · 2012: 274
- FWCI
- 14.32
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › ATP Synthase and ATPases Research
- Keywords
- multidrug resistance, drug efflux pumps, chemoresistance, cancer chemotherapy, drug resistance mechanisms, metastatic cancer
- MeSH terms
- Adenosine Triphosphate, Antineoplastic Agents, Breast Neoplasms, Female, Forecasting, Multigene Family, Humans, Leukemia, Neoplasm Proteins, Neoplasms, Organ Specificity, Permeability, Structure-Activity Relationship, Drug Design, Xenobiotics, Biomarkers, Drug Resistance, Multiple, ATP-Binding Cassette Transporters, Drug Resistance, Neoplasm, ATP Binding Cassette Transporter, Subfamily B, Member 1, ATP-Binding Cassette, Sub-Family C Proteins, Multidrug Resistance-Associated Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.